Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Interleukin
    (61)
  • IL Receptor
    (30)
  • TNF
    (13)
  • IFNAR
    (4)
  • Apoptosis
    (3)
  • Autophagy
    (3)
  • COX
    (3)
  • NF-κB
    (3)
  • NOD-like Receptor (NLR)
    (3)
  • Others
    (6)
Filter
Search Result
Results for "

Interleukin Related

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    89
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    1
    TargetMol | Compound_Libraries
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    19
    TargetMol | Inhibitory_Antibodies
  • Natural Products
    22
    TargetMol | Natural_Products
  • Recombinant Protein
    22
    TargetMol | Recombinant_Protein
  • Isotope Products
    1
    TargetMol | Isotope_Products
  • Antibody Products
    1
    TargetMol | Antibody_Products
  • Disease Modeling
    3
    TargetMol | Disease_Modeling_Products
  • Cell Research
    1
    TargetMol | Inhibitors_Agonists
Tocilizumab
T9911375823-41-9
Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Benralizumab
MEDI-563, BIW-8405
T104971044511-01-4
Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.
  • Inquiry Price
Size
QTY
Ixekizumab
LY2439821
T381051143503-69-8
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis.
  • Inquiry Price
Size
QTY
Basiliximab
CHI 621
T73698179045-86-4
Basiliximab (CHI 621) is a chimeric mouse human IgG1 monoclonal recombinant antibody targeting the interleukin-2 receptor, demonstrating potent immunosuppressive activity for use in kidney transplantation studies.
  • Inquiry Price
Size
QTY
Nemolizumab
CIM331
T767241476039-58-3
Nemolizumab (CIM331) is a humanized monoclonal antibody targeting the human interleukin-31 receptor A, inhibiting IL-31 binding and subsequent signal transduction. It is useful for studying atopic dermatitis with pruritus.
  • Inquiry Price
Size
QTY
Fletikumab
NNC 0109-0012, NN-8226, Anti-IL-20
T767471357158-22-5
Fletikumab (NNC0109-0012) is a monoclonal antibody that inhibits IL-20, primarily used in research on rheumatoid arthritis and psoriasis.
  • Inquiry Price
Size
QTY
Fezakinumab
ILV 094
T767751007106-86-6
Fezakinumab is a potent monoclonal antibody to interleukin-22 (IL-22). Fezakinumab can be used to study immune system diseases and inflammation-related conditions such as psoriasis, rheumatoid arthritis and atopic dermatitis.
  • Inquiry Price
Size
QTY
Talacotuzumab
JNJ 56022473, CSL 362
T768831826831-79-1
Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has a high affinity for CD123, CD32b c, CD16-158F and CD16-158V, with KD of 0.43 nM, 188 nM, 46 nM and 16.8 nM, respectively. Talacotuzumab inhibits IL-3 signaling in target cells by inhibiting IL-3 binding to CD123. Talacotuzumab induces mutations in the Fc region to increase affinity for CD16 (FCγriiia), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab inhibits leukemia cell growth in xenografted mouse models of acute myeloid leukemia (AML).
  • Inquiry Price
Size
QTY
Oxelumab
Ro 49-89991, R 4930, huMAb OX 40L
T768911186098-83-8
Oxelumab (R 4930) is a human monoclonal antibody targeting OX40L, and could be used to study asthma.
  • Inquiry Price
Size
QTY
Astegolimab
RG 6149, MSTT 1041A
T769102173054-79-8
Astegolimab (RG 6149) is a humanised IgG2 monoclonal antibody that targets the IL-33 receptor and inhibits IL-33 signalling. Astegolimab is used in the study of chronic obstructive pulmonary disease (COPD) and severe asthma in adults.
  • Inquiry Price
Size
QTY
Cergutuzumab amunaleukin
RO 6895882, RG 7813, CEA-IL2v
T769441509916-03-3
Cergutuzumab amunaleukin (CEA-IL2v) is a CEA-targeted IL-2 variant immunocytokine for combination cancer immunotherapy with immunostimulatory and anti-tumor activities for the study of solid cancers.
  • Inquiry Price
8-10 weeks
Size
QTY
Vixarelimab
RO-7622888, RG-6536, KPL-716
T769562243320-83-2
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor, inhibiting IL-31 and OSM signaling. It can be used to study severe nodular itch and idiopathic pulmonary fibrosis.
  • Inquiry Price
Size
QTY
Melrilimab
GSK3772847, GSK 3772847, CNTO-7160, CNTO7160
T770832222865-46-3
Melrilimab (GSK 3772847) is an IgG antibody targeting IL-33R with high affinity for IL1RL1 ST2 DER4 FIT-1 and can be used in asthma research.
  • Inquiry Price
Size
QTY
Nemvaleukin alfa
RDB-1450, RDB1450, Nemva, ALKS4230, ALKS 4230
T770962315268-27-8
Nemvaleukin alfa (ALKS 4230) is an interleukin 2 fusion protein, a selective agonist of the medium-affinity IL-2 receptor, produced by fusion of the IL-2Ralpha subunit of the circularly arranged interleukin-2 (IL-2) and IL-2 receptor (IL-2R) complexes, which drives antitumor Immunity and inhibits tumor growth in small cell lung cancer.
  • Inquiry Price
Size
QTY
Simlukafusp alfa
RO6874281, RO 6874281, RG-7461, FAP-IL2v, FAPIL2v, aFAP-IL2v
T771691776942-10-9
Simlukafusp alfa (FAP-IL2v) is a tumor-targeting immune cytokine, a human IgG1 antibody, with antitumor activity and immunostimulatory properties that potentiate in vitro and in vivo activity of therapeutic antibodies mediating antibody-dependent or T-cell-independent cytotoxicity (TDCC) and programmed death ligand 1 (PD-L1) checkpoint inhibition.
  • Inquiry Price
Size
QTY
Ziltivekimab
WBP-216, WBP216, MEDI5117, MEDI 5117, EX-6018, EX6018
T9901A-0742226654-05-1
Ziltivekimab (MEDI 5117) is a CHO-expressed humanized monoclonal antibody targeting IL-6 IFNb2 for use in immune system diseases.
  • Inquiry Price
Inquiry
Size
QTY
Ustekinumab
T9913815610-63-0
Ustekinumab is an anti-IL-12 IL-23 IgG1κ human monoclonal antibody.
  • Inquiry Price
Size
QTY
Mepolizumab
SB 240563
T9962196078-29-2
Mepolizumab (SB 240563) is a humanized monoclonal antibody that neutralizes IL-5, and can be utilized in research on severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Ordesekimab
PRV-015, AMG 714
T76892879293-15-9
Ordesekimab (AMG 714) is a human IgG1 κ-anti-IL-15 (Interleukin Related) monoclonal antibody. Ordesekimab binds competitively to IL-15, inhibiting the interaction of IL-15 with the common gamma chain of the IL-2Rβ and IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab can be used to study non-reactive celiac disease (NRCD).
  • Inquiry Price
Size
QTY